Literature DB >> 3346572

Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs.

M J Chou1, T H Lee, A Hatzakis, T Mandalaki, M F McLane, M Essex.   

Abstract

Sera from hemophiliacs were analyzed for antibodies to human immunodeficiency virus type 1 (HIV-1) by using radioimmunoprecipitation (RIP), western blotting (WB) with nonreducing buffer (NR), and WB with reducing buffer (R). We analyzed envelope gp160, gp120, and gp41; pol gene proteins p64, p53, and p34; and gag gene protein p24. Of 215 samples positive for reactivity to gp160 and gp120(RIP), antibodies to p24 were undetectable in 2 (0.9%), to gp41 in 9 (4.2%), to the pol antigens in 5 (2.3%), to gp120(NR) in 3 (1.4%), and to gp120(R) in 55 (25.6%). By sequential analysis of samples, antibodies to gp120(NR), gp120(R), p24, gp41, p64/53, and p34 were observed later in the course of infection than were antibodies to gp120(RIP) or gp160. This result suggests caution against reliance on WB as the "gold standard." A significantly higher rate of progression to AIDS-related complex was found for individuals lacking antibodies to gp120(R). It is possible that antigenic domains represented by gp120(R) may play a role in the pathogenesis of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346572     DOI: 10.1093/infdis/157.4.805

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Characterization of a discontinuous epitope of the human immunodeficiency virus (HIV) core protein p24 by epitope excision and differential chemical modification followed by mass spectrometric peptide mapping analysis.

Authors:  E O Hochleitner; C Borchers; C Parker; R J Bienstock; K B Tomer
Journal:  Protein Sci       Date:  2000-03       Impact factor: 6.725

2.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41.

Authors:  W R Lee; X F Yu; W J Syu; M Essex; T H Lee
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

4.  Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera.

Authors:  F Ozyörük; W P Cheevers; G A Hullinger; T C McGuire; M Hutton; D P Knowles
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

5.  Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2.

Authors:  B Janvier; P Archinard; B Mandrand; A Goudeau; F Barin
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

6.  Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.

Authors:  W J Syu; W R Lee; B Du; Q C Yu; M Essex; T H Lee
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

7.  Analysis of antibody responses to phenotypically distinct lentiviruses.

Authors:  O Kajikawa; M D Lairmore; J C DeMartini
Journal:  J Clin Microbiol       Date:  1990-04       Impact factor: 5.948

8.  Host-virus interaction as defined by amplification of viral DNA and serology in lentivirus-infected sheep.

Authors:  S J Brodie; L D Pearson; G D Snowder; J C DeMartini
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

9.  The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4.

Authors:  W J Syu; J H Huang; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

10.  The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

Authors:  D Chargelegue; C M Stanley; C M O'Toole; B T Colvin; M W Steward
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.